Eric Palmer

Biography for Eric Palmer

Eric Palmer, Senior Editor

Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at epalmer@fiercemarkets.com.

Articles by Eric Palmer

More cuts as Sun Pharma pulls Ranbaxy into the fold

Sun Pharmaceutical continues to cut staff, as it continues to integrate Ranbaxy Laboratories, which it bought in a $4 billion deal this year. After the recent departure of about 150 top execs, the Economic Times says the drugmaker is now targeting R&D operations, with 15 departures at hand.

Cardinal reports rising revenues and says next year looks even better

After losing its business with Walgreens a few years back, drug wholesaler Cardinal Health has taken steps to beef up its operations and those keep paying off. The company today reported both Q4 and year-end numbers with enough growth in sales and profits to feel good about raising its projections for fiscal 2016.

FDA issues draft guidance on quality manufacturing metrics

Last January, Janet Woodcock, director of FDA's Center for Drug Evaluation and Research, initiated the Office of Pharmaceutical Quality. The idea is for it to work up guidelines that will push even reluctant drugmakers toward quality manufacturing and establish a risk-based method for setting inspections. The office is now providing an idea of how that will work.

Regulators in Europe propose bans on plants in China and India

According to reports posted on the EudraGMDP site, regulators from Italy recommended bans on specific products made by Jinan Jinda Pharmaceutical in Shandong Province in China and Wuxi Jida Pharmaceutical in Jiangsu City, China, as well as Parabolic Drugs in Haryana, India.

Indian drugmaker in hot water with FDA over forged records

FDA investigators found a record-keeping mess at an Indian drug manufacturer that they say raises concerns about the quality of the active pharmaceutical ingredients that it shipped for use in U.S. drugs.

Hikma gets large U.S. plant in Boehringer Ingelheim generics deal

Last year when Hikma bought Boehringer Ingelheim's Ben Venue injectable business, it decided not to reopen its long-troubled Bedford, OH, plant. But with a $2.65 billion deal announced today for Boehringer's Roxane generics business, it gets a U.S. manufacturing plant that it says it likes the looks of.

EU ban on more than 700 drugs set for Aug. 21

The European Union will impose a ban starting Aug. 21 on more than 700 drugs that were bioequivalency tested by India's GVK BioSciences after inspectors raised questions about its procedures.

Androxy returns to market after 9-month lapse

Upsher-Smith had to quit shipping fluoxymesterone tablets last fall when its supplier quit making the API for Androxy. The problem was that Upsher-Smith is the only supplier in the U.S. for the drug, which is used to treat breast cancer in women and low testosterone in men. Now Upsher-Smith says Androxy is back.

Teva expands recall of cancer drug Adrucil

Teva Pharmaceutical Industries voluntarily recalled 8 lots of a cancer drug a couple of months ago after rubber particles were found in some containers. Now the generics maker says the problem is more widespread than it first thought and more units will need to be retrieved.

Hospira recall of ketorolac now close to 40 million vials

After recalling 18 million vials last January of a painkiller commonly used in surgery, sterile injectables maker Hospira indicated that it was on top of the problem. But the company now says new manufacturing issues have cropped up that have led it to recall more than 20.7 million more vials of ketorolac, a drug on the FDA shortage list.